Are You Considering How Best To Manage And Remove Aggregates From Your mAb Process?

Source: MilliporeSigma

Aggregates in mAb therapeutics pose a risk to patients. Are you considering how best to manage and remove aggregates across your template?

Herb Lutz, Global Consultant, opens this 6-part video series with a discussion around the formation of protein aggregates and their regulatory importance. An overview of methods and technologies will also be reviewed for managing or removing aggregates from your mAb process including upstream, chromatography, virus filtration, ultrafiltration/diafiltration (UF/DF), and final formulation.